Conference Coverage

Chemoimmunotherapy, chemoradiotherapy add no survival in pancreatic cancer

Publish date: June 12, 2013

 

AT THE ASCO ANNUAL MEETING 2013

LAP 07 was sponsored by Groupe Cooperateur Multidisciplinaire en Oncologie. Dr. Hammel reported honoraria from Roche.

pwendling@frontlinemedcom.com

Pages

Recommended Reading

Simeprevir keeps HCV at bay in treatment-naive and experienced patients
MDedge Internal Medicine
Guidelines accurately predict risk of common bile duct stones
MDedge Internal Medicine
Cohort study shows link between colonoscopy, overall mortality
MDedge Internal Medicine
Bariatric surgery less efficacious in blacks
MDedge Internal Medicine
Nosocomial infection in cirrhotic patients boosts acute kidney injury risk
MDedge Internal Medicine
EET and esophagectomy yield similar cancer-free survival
MDedge Internal Medicine
Mesalamine a bust at diverticulitis prevention
MDedge Internal Medicine
Benefits of laparoscopic over open colectomy decrease with operative time
MDedge Internal Medicine
Telaprevir-based triple-drug therapy benefits CHC patients with ESRD
MDedge Internal Medicine
TLR9 agonist active against ulcerative colitis in small study
MDedge Internal Medicine